

Year-end report

January 1 – December 31, 2023

The fourth quarter in figures

- Net sales were TSEK 5,764 (4,962), +16%.
- The loss after tax was TSEK 20,541 (15,460).
- The loss per share was SEK 0.17 (0.23).
- The cash flow from current operations was negative in the amount of TSEK 17,352 (14,593).
- The gross margin was 73.5% (61.4%).
- Electrode sales volume increased by 5% and was 12,044 (11,444) units. Repeat sales of electrodes to existing customers increased by 25%.

January - December in figures

- Net sales were TSEK 23,245 (17,890), +30%.
- The loss after tax was TSEK 55,585 (43,174).
- The loss per share was SEK 0.51 (0.63).
- The cash flow from current operations was negative in the amount of TSEK 51,984 (44,466).
- The gross margin was 69.0% (62.8%).
- Electrode sales volume increased by 24% and was 51,920 (41,712) units. Repeat sales of electrodes to existing customers increased by 31%.

Important events during the quarter

- Overall sales increased by 16% (+10, before currency effects). Sales in Germany increased by 36% (26% in local currency). Sales in the US skin cancer market increased by 34% while the sales within the skin barrier segment decreased by 46%.
- SciBase entered into a collaboration agreement with the Skin and Cancer Institute, a leading dermatology network in California with more than 50 clinics, to pilot Nevisense in several of their California locations.
- SciBase entered into a collaboration agreement with the Skin and Cancer Reconstructive Surgery Center in California. This partnership means that an additional dermatology network will help to introduce Nevisense to a broader US market. .
- A nominating committee for the Annual General Meeting in 2024 was appointed.

Important events after the end of the period

- No significant events have occurred after the end of the period.

Financial overview

THE GROUP	Oct 1 - Dec 31		Jan 1 - Dec 31	
	2023	2022	2023	2022
Net sales, SEK ths	5 764	4 962	23 245	17 890
Gross margin, %	73,5%	61,4%	69,0%	62,8%
Equity/Asset ratio, %	66,9%	50,6%	66,9%	50,6%
Net indebtedness, multiple	0,49	0,98	0,49	0,98
Cash equivalents, SEK ths	34 121	18 832	34 121	18 832
Cashflow from operating activities, SEK ths	-17 352	-14 593	-51 984	-44 466
Earnings per share (before and after dilution), SEK	-0,17	-0,23	-0,51	-0,63
Shareholder's equity per share, SEK	0,36	0,37	0,40	0,37
Average number of shares, 000'	119 831	68 475	107 980	68 475
Number of shares at closing of period, 000'*	119 831	68 475	119 831	68 475
Share price at end of period, SEK	0,83	3,82	0,83	3,82
Number of sold electrodes, pieces	12 044	11 444	51 920	41 712
Average number of employees	26	21	23	20

Definitions and a glossary are provided on page 19



2024 Winter Clinical Dermatology Conference in Miami

SciBase participated at the 2024 Winter Clinical Dermatology Conference in Miami. The second annual Winter Clinical Miami conference is a 4-day CME course that educates dermatologists on innovative news within Medical, and Surgical Dermatology. This prestigious CME course attracts over 400 dermatologists from the US and is considered to be one of the leading educational events for dermatology professionals. Above Dr Goldenberg, Assistant Professor of Dermatology and Pathology at The Icahn Sinai School of Medicine at Mount Sinai in New York City, and CEO Pia Renaudin at the booth.



Comment by CEO Pia Renaudin

“ 14th consecutive quarter of overall sales growth, momentum in the US and improved gross margin ”

Highlights Q4

- Sales in Q4 increased by 16% to MSEK 5.7 (4.9).
- Germany continues to deliver excellent growth, 36% (26% in local currency) in the Q.
- The US is back on a growth trajectory, +34% for the quarter.
- The gross margin reached 73.5 (61.4) % in the quarter with the electrode margin exceeding 80%.
- Additional collaborations with large dermatology networks, Skin and Cancer Institute and Skin and Cancer Reconstructive Surgery Center, both in California, initiated.


In my initial period as CEO, I have been creating a roadmap for SciBase rapid transition into a robust commercial company. Revisiting our strategy, I am confident that with a more focused approach, we can significantly enhance value for our shareholders, the healthcare sector, and patients.

Continued sales growth

In the fourth quarter, we reported a continued overall growth of 16 %. Adjusted for exchange rates the growth was 10%. **Germany continued to deliver strong sales growth of 36%, despite inventory build-up in Q3** with electrode sales volumes growing by 17%.

The US turned to growth with an increase of 34%. The US growth is an important milestone, as we are working to secure broad reimbursement for Nevisense. We added two new dermatology networks who now uses our technology in California and have started to file claims. Our objective is to establish Nevisense as the standard of care in the U.S.

With the success in Germany, we have shown that Nevisense is an attractive and commercially successful product, which today generates a positive cash flow for the Group. In Europe we will build on the success in Germany by expanding into Switzerland and Austria. We have hired a sales manager with an excellent track record, who already has the experience of building up businesses in dermatology, he will start on March 1.



Percentage quarterly sales growth compared to the same quarter in the previous year.

Strategy

Our commercialization strategy is focused on skin cancer - an important and growing market predominantly found in countries with populations who have a significant need for reliable and early diagnosis. This targeted approach enables us to communicate effectively with healthcare providers and payers, ensuring that our resources are allocated to areas with the highest potential for value creation.

We estimate that we can reach profitability with an installed base of around 800-1,000 systems, each utilizing 6-7 electrodes on a weekly basis. We currently have an installed base of around 400 customers in Germany of which approximately 200 clinics are averaging just below six electrodes per week.

US focus

Our new organization is driving and supporting our expanded customer base in Texas, California and the East coast. In the quarter we added three new dermatology chains at six locations. They are now implementing and starting to use Nevisense. Our short-term focus in the US is to drive reimbursement which is done by our customers using Nevisense and then submitting claims to the payers. With our customers and with our strong key opinion leader support we are making good progress.

US sales are back on growth in the last quarter with +34% and we expect the US to continue to deliver sales growth.

Last week I was at the Congress Winter Clinical in Miami. Several key opinion leaders presented Nevisense in their plenary talks. Our booth was well visited, and we got many new leads from interested dermatologists. There is clearly a great interest and need for our technology.

Barrier – atopic dermatitis

Our limited launch of atopic dermatitis assessment in Germany is going well and we have received encouraging feed-back from the key customers who have been part of the launch. The strategy is to initially target our customer base. In the quarter sales within this segment decreased by 46% as Q4-22 included two larger orders for clinical trials. This is normal as research- and partner sales occur irregularly and with large volumes.

Improved gross margin

Our goal is to achieve a stable gross margin over 70%. In Q4 we reached a gross margin of 73.5% with a margin of 80% on the electrode. This improved margin is driven by a favourable product mix - higher US electrode sales, price increases on the electrode in Germany and positive currency effects. The results on



Q4 and over the year strengthens our belief that our target is achievable.

Financing

The Board of Directors regularly reviews the company's existing and forecasted cash flows to ensure that the company has the funds and resources necessary to pursue the operations and strategic focus adopted by the Board. Given our positive momentum in the US and the expansion in Europe we believe that SciBase has a very interesting journey ahead of us. We are working to improve our communication and we had our capital markets day on Jan 25. We welcome those of you that haven't seen it yet to see the presentation here:

<https://investors.scibase.se/en/node/709>

In summary, the opportunities for SciBase in 2024 are exciting. With a unique AI driven platform, we are investing in growth. We are committed to our vision to pioneer prediction and prevention in dermatology and to empower healthcare professionals to improve diagnostic accuracy, enable disease monitoring, and

facilitate early intervention of skin cancer and skin disorders.



*Pia Renaudin, CEO
Sundbyberg February 21st, 2024*

SciBase in brief

About SciBase

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercialize Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been Nasdaq First North Growth Market exchange since June 2, 2015.

For more information, please visit www.scibase.com

Business model

The company's business model is based on customers initially purchasing a Nevisense platform and consumables (electrodes).

Short facts

- Skin cancer is the most common and fastest-growing form of cancer in the world.
- Melanoma is the most dangerous form of skin cancer with a high mortality rate if not detected early.
- More than 5 million cases of skin cancer detected annually in the US.
- In 2020 skin cancer caused 120,000 deaths.
- SciBase addressable market, in skin cancer alone, is estimate to SEK 4 billion.
- The Nevisense® platform provides physicians with an objective instrument to support better diagnoses.

Certified Advisor (CA)

Vator Securities

Email: ca@vatorsec.se


Tel: +46 8 580 065 099

"I work every day with the management of different allergic diseases in children, and it is a growing problem. Allergic diseases have a natural progression with atopic dermatitis being the first to manifest, often already in infancy, followed by other allergic diseases, such as food allergy and allergic asthma. The ability to identify these children early, will help to develop preventive strategies for allergic diseases, and Nevisense is an extremely promising method that has potential for early prediction of those children", says Dr. Caroline Reduit at the Children's Hospital of Eastern Switzerland.


Skin barrier – a hot topic

- Atopic dermatitis (eczema) is the most common chronic disease with over 200 million patients in the US and Europe and affects about 20% of infants and 7% of adults.
- Skin barrier related diseases such as food allergy and atopic dermatitis (eczema), are a growing problem and there is a large global unmet need for tools for prediction, measurement and management. The market for atopic dermatitis is expected to grow at ~10% annually until 2030.
- Impaired skin barrier is growing with long-term trends such as climate change, increased air pollution, change and loss of biodiversity


Sales, rolling-12




Sales per segment - rolling-12



Gross margin (%) - development



Income after tax



The Fourth quarter

Net Sales

Net sales for the fourth quarter of 2023 were TSEK 5,764 (4,962), an increase of 16%. Cleared for currency effects the sales increased by 33%. The increased sales are mainly due to continued good sales of electrodes and devices in Germany, a return of US growth and currency effects. The growth is balanced by lower sales with the skin barrier segment as Q4-2022 included two large orders to clinical studies. Germany showed a good growth in the quarter (+36%) through increased sales of electrodes to both new and existing customers. One of the driving forces behind the growth is the new indication NMSC (non-melanoma skin cancer). In the US sales returned to growth and increased by 34% compared to Q4-22. Several new collaborations with larger dermatology networks accounts for this growth.

Sales of devices were TSEK 649 (694) and sales of electrodes to TSEK 5,116 (4,268) which is the best electrode sales Q to date. The sales within the new skin barrier application were TSEK 480 (889) in the period. Q4-22 included two larger orders to clinical trials. Given the nature of research projects, sales will vary between the quarters.

Sales in Germany in the skin cancer area accounted for 82 (74%) of the sales in the period and increased by 36% compared to Q4 2022. In local currency the sales in Germany increased by 26%.

Sales in the US in the skin cancer segment accounted for 9 (8)% of the sales in the period. Sales in the US are dependent on reimbursement and a first positive reimbursement decision was obtained in April 2023 when two Medicare regions updated the level of reimbursement through their fee-schedule. This enables us to initiate expansion and drive sales within the regions

and for the patient group where reimbursement is now in place. In the period, new key customers in the form of dermatology networks have been established in new regions, including California.

Electrode sales in the quarter reached 12,044 (11,444) sold, an increase of 5%, the relatively lower growth rate is mainly due to inventory build-up in Germany in Q3 following an announced price increase from August 1 and lower barrier sales. In Germany, the total sales of electrodes within skin cancer in volume increased by 17%, US electrode volumes grew by 39% while barrier volumes decreased by 63%. Total repeat sales of electrodes increased by 25%.

Operating profit/loss

The operating loss for the period October - December 2023 was TSEK 16,599 (13,634), an increased loss of TSEK 2,965. The increased sales and improved gross margin contributed to an improvement in earnings, which was balanced by increased sales and marketing expenses through increased investments in the US and currency effects. The total operating expenses increased in the period by TSEK 4,155. The operating income was negatively affected by currency effects with around MSEK 0.3.

The gross margin in the period was 73.5 (61.4%). The improved margin is primarily thanks to higher electrode sales, currency effects and a during 2022 and 2023 performed price increase on the electrode in Germany. SciBase is focusing on the margin and the production cost for the electrode and in the quarter the margin for the electrode was close to 80%. When cleared for currency effects the overall gross margin would have been closer to 72%. The overall margin remains very dependent on

electrode production and sales volumes and will vary between quarters.

Sales and marketing expenses increased by TSEK 2,207 and were TSEK 12,339 (10,132). The expense increase was primarily due to increased US resources and marketing activities and currency effects.

Administration expenses for the period were TSEK 3,435 (3,195), an increase of TSEK 240. The increase was mainly due to expenses related to the recruitment of a new CEO.

Development expenses for the period were TSEK 5,165 (3,036), an increase of TSEK 2,129. The increase was mainly due to ongoing projects within product development and manufacturing.

The financial costs/income have negatively affected the result in the period as a result of currency translation effects on receivables from the subsidiaries when the Swedish krona strengthened at the end of the year

January - December

Net Sales

Net sales for the full year 2023 were TSEK 23,245 (17,890), an increase of 30%. Cleared for currency effects the sales increased by 21%. The increased sales are mainly due to continued good sales of electrodes and devices in Germany and currency effects. US sales decreased by 37% compared to 2022 partly due that 2022 included the initial start-up sales of 10 Nevisense systems to SciBase partners in the US and to some extent because of reduced usage by some customers having received reimbursement denials from certain commercial insurance companies and thus reducing their usage while waiting for improved reimbursement. However, during Q4 the negative trend has changed to a positive trajectory. Germany continues to show a good growth (+48%) through both sales of electrodes and sales of devices to new customers. One of the drivers for this growth is the new NMSC (non-melanoma skin cancer) indication.

Sales of devices were TSEK 2,342 (2,571) and sales of electrodes to TSEK 20,903 (15,319). The sales within the new skin barrier application were TSEK 1,419 (1,583) in the period. In 2022 two larger orders for clinical trials were sold. These sales are for research purposes. Given the nature of research projects, sales will vary between the quarters.

In 2023 sales in Germany in the skin cancer area accounted for 87 (76%) of the sales during the year and increased by 48% compared to 2022. In local currency the sales in Germany increased by 36%.

Sales in the US for the full year in the skin cancer segment accounted for 7 (15)% of the sales. Sales in the US are dependent on reimbursement and a first positive reimbursement decision was obtained in April 2023 when two Medicare regions updated the level of reimbursement through their fee-schedule. This enables us to initiate expansion and drive sales within the regions and in the patient groups where reimbursement is now in place, as an example, a new collaboration agreement has been initiated with BARE Dermatology in Texas. Furthermore, additional

Cash flow, investments and financial position

At the beginning of the period, cash and cash equivalents was TSEK 52,353 and, at the end of the period, was TSEK 34,121.

Cash flow from current operations for the period was negative to the amount of TSEK 17,352 (14,593), of which changes in working capital amounted to negative TSEK 948 (negative 1,625) which was mainly attributable to inventory build-up following the decision to move the production of Nevisense in-house, decreased liabilities which were balanced by decreased receivables. Total cash flow for the period was negative to the amount of TSEK 18,107 (negative 15,439).

Net investments in tangible assets for the period was TSEK 83 (208). Investments in intangible assets for the period was TSEK 0 (0).

Depreciation of tangible assets was charged against earnings for the period to the value of TSEK 866 (958) of which TSEK 697 (724) are due to leased assets.

customers in the form of dermatology networks have been established in other regions such as California where the work is now ongoing to achieve reimbursement.

The total sales volume of electrodes for the full year was 51,920 (41,712), an increase of 24%. In Germany, the total sales of electrodes within skin cancer in volume increased by 34%, in the US volumes decreased by 32%. Total repeat sales of electrodes increased by 31%.

Operating profit/loss

The operating loss for the full year 2023 was TSEK 53,939 (46,419), an increased loss of TSEK 7,520. The increased sales and improved margin contributed to an improvement in earnings, which was balanced by increased sales and marketing expenses through increased investments in the US and currency effects. The total operating expenses increased in the period by TSEK 12,323. The operating income was negatively affected by currency effects with around MSEK 0.2.

The gross margin for the year was 69.0 (62.8%). The improved margin is mainly driven by price increases on the electrode in Germany, currency effects and an improved production cost per electrode. SciBase is focusing on the margin and the production cost for the electrode and in the period the margin for the electrode was close to 75%. When cleared for currency effects the overall gross margin would have been closer to 67%. The overall margin remains very dependent on electrode production and sales volumes and will vary between quarters.

Sales and marketing expenses increased by TSEK 6,920 and were TSEK 42,543 (35,623). The expense increase was primarily due to increased US resources and marketing activities and currency effects.

Administration expenses for the year were TSEK 12,017 (11,183), an increase of TSEK 834. The increase was mainly due to recruitment expenses of a

new CEO, the implementation of a new business system as well as audit expenses and consultants.

Development expenses for the year were TSEK 15,348 (10,816), an increase of TSEK 4,532. The increase is mainly due to ongoing projects within product development, manufacturing and clinical studies.

Cash flow, investments and financial position

At the beginning of the period, cash and cash equivalents was TSEK 18,832 and, at the end of the period, was TSEK 34,121.

Cash flow from current operations for the period was negative to the amount of TSEK 51,984 (negative 44,466), of which changes in working capital amounted to negative TSEK 2,133 (negative 1,951) which was mainly attributable to increased inventory

of Nevisense and components due to inventory build-up prior to relocation of manufacturing from external to in-house manufacturing and decreased liabilities which was balanced by decreased receivables. Total cash flow for the period was positive to the amount of TSEK 15,314 (negative 47,327). During the second quarter 2023 the Company closed a fully underwritten share issue raising net, after issue costs, approximately MSEK 70.

Net investments in tangible assets for the period was TSEK 383 (381). Investments in intangible assets for the period was TSEK 0 (0).

Depreciation of tangible assets was charged against earnings for the period to the value of TSEK 3,388 (3,651) of which TSEK 2,733 (2,896) are due to leased assets.

Other disclosures

Shareholders

At the end of the year, SciBase Holding AB had approximately 3,218 shareholders. Per December 30, the five largest shareholders represented approximately 43.4% of the capital and votes. The total number of shares per December 29, 2023, was 119,831,437. The largest shareholders as per December 29, 2023, were Gell Group (11%), Avanza pension (10%), SIX SIS AG – Van Herk (9%), Nordnet Pension (7%) and Stockholms Elbolag (6%).

Market overview

SciBase is active within both skin cancer detection and skin barrier assessment. SciBase's Nevisense platform addresses multiple sizeable clinical application areas.

Skin cancer

Skin cancer is believed to be the most common form of cancer in the world. More than 5 million cases of skin cancer are reported every year in the US alone, which is more than all other cancers combined. SciBase estimate that the total addressable market potential for SciBase to be around 400 million USD per year or approximately BSEK 3.7.

The population of non-melanoma skin cancer patients includes more than ten times the number of patients compared to the melanoma patient population. SciBase estimates that the potential for the use of Nevisense amounts to at least 4 million examinations or tests annually. Given this, non-melanoma skin cancer is estimated to have a total market potential of approximately SEK 1.4 billion annually.

Skin barrier

An exciting application area is skin barrier assessment. The skin barrier stops irritants, allergens etc. entering, and water from leaving the body. An impaired skin barrier at birth can be a predictor of the development of Atopic Dermatitis (AD) or eczema. The development of AD often precedes the development of other atopic diseases such as food allergies, allergic rhinitis and allergic asthma. The ability to easily detect

an impaired skin barrier can help detect, manage and treat atopic diseases before the development of AD. There is a high interest from the research community and this group is the short-term sales target within the barrier area.

As many as up to 20% of all children and 7% of all adults suffers from atopic dermatitis. The application area includes disease development prediction in infants, diagnostic and therapy selection tests in a clinical setting, and regular tests in the home in order to monitor and manage the disease. The total number of measurements for all patients with atopic dermatitis could potentially exceed the tens of million per year.

Initially SciBase focuses on the launch of atopic dermatitis in Germany and sales towards researchers.

Employees

At the end of the period, the number of employees amounted to 27 (23), of whom 44 (30)% were women. This includes the production employees at our Uppsala electrode production facility and salespeople in Germany and the US.

Financing

The Board of Directors regularly reviews the company's existing and forecasted cash flows to ensure that the company has the funds and resources necessary to pursue operations and strategic focus adopted by the Board. The company's long-term cash requirements are determined by how successful the Company will be able to commercialize its products. Commercialization is, in turn, dependent on a variety of factors that will affect the need, including costs related to being included in insurance systems, granted compensation levels therein, marketing costs and obtaining and enforcing regulatory requirements.

During the first quarter of 2023 the Board of Directors of SciBase Holding AB (publ) resolved, by virtue of the authorization from the annual general meeting on 18 May 2022, to carry out a fully guaranteed issue of new shares with preferential rights for existing shareholders of approximately SEK 79.6

million before transaction costs. The subscription price was SEK 1.55 per new share. The share capital increased by SEK 2,567,816.5 through the issue of 51,356,330 new shares. The net proceeds after issue costs were approximately SEK 70 million.

As of December 30, 2023, the Group's cash and cash equivalents amounted to SEK 34.1 million. Based on the current strategic plan, the board assesses that the group needs additional capital during the next 12-month period and is currently evaluating different financing options. Based on the positive sales development in Germany, the positive reimbursement decision in the US, the great interest in the company's barrier products and the previously communicated collaboration with Johnson & Johnson the board assesses that the company has good conditions to finance the capital requirement that the decided plan requires. Should crucial conditions not be fulfilled, there is however a significant uncertainty factor regarding the company's financing of the business going forward.

Transactions with related parties

During the year, the parent Company SciBase Holding AB has invoiced TSEK 4,744 (4,744) to the fully owned subsidiary SciBase AB, which corresponds to a 100% of the parent Company's turnover in the year. In addition, the company has a separate consulting agreement in place with the board member Matt Leavitt (appointed in 2021). The agreement was entered into prior to him being appointed as a board member and relates to consultancy support for the regional reimbursement processes and US market introduction as well as Nevisense rollout guidance following positive reimbursement decisions. The agreement has a one-year duration with the option to extend. In the period he was remunerated KUSD 300 (300) for services under this agreement. During the recruitment process for a new CEO, the chairman of the board, Tord Lendau, took over certain operational parts of the CEO role and has invoiced a consulting fee for this. In total, this amounts to KSEK 964 during the period. During the reporting period there were no other transactions with related parties that had any material impact on the Group or Parent Company's position and earnings.

Risks and uncertainty

The principal risks and sources of uncertainty for SciBase include, albeit not exclusively, financial risks, such as the future earnings trend, financing, and currency and credit risks. In addition to market risks, there are also risks associated with SciBase's operations, such as obtaining necessary approval from authorities, product development, patents and intellectual property rights, product responsibility and forward-looking information. Nor are there any guarantees that the Company will be able to secure the financial resources necessary to conduct its operations. Further information on the Company's risk exposure can be found on pages 34-37 of SciBase's 2022 Annual Report.

Parent Company

SciBase Holding AB (publ), corporate identity number 556773-4768, is the Parent Company of the Group.

The company was formed in 2009 following a restructuring of the Group. The actual operations are conducted by the fully owned subsidiary SciBase AB.

As per December 30, 2023, there were two employees, the CEO and the Groups finance department. The operations consist of consulting activities for the rest of the Group. The company's main task is of a financial nature – to fund the Group's operational activities.

Net sales for the year reached TSEK 4,744 (4,744). The loss for the year amounted to TSEK 37,072 (30,344). The Company's net sales consist of invoiced consultancy fees to the fully owned subsidiary SciBase AB.

The shareholders' contributions to the fully owned subsidiary SciBase AB from 2016 and is charged to earnings and not booked as a financial tangible asset. The shareholders contribution expensed during the year was MSEK 29.4 (24.0).

Significant events during the quarter

SciBase entered into a collaboration agreement with the Skin and Cancer Institute to pilot Nevisense in several of their California locations. The Skin and Cancer Institute is a world-renowned dermatology practice group of dermatologists and skin cancer surgeons, and was the first dermatology practice group in California to bring AI-driven technology to their patients for skin cancer detection. With more than 50 offices across a three-state network comprised of California, Arizona and Nevada, they are one of the largest dermatology groups in the country. The collaboration will provide the Skin and Cancer Institute's group with Nevisense, the only AI-driven FDA approved test for early melanoma detection for dermatologists at point-of-care.

SciBase announced that its US coast-to-coast momentum continued with a collaboration agreement with the Skin and Cancer Reconstructive Surgery Center ("SCARS Center") in California. This partnership will help further introduce Nevisense to a broader US market.

The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2024:

Thomas Axelsson former CEO Vitrolife AB (Gell Group),
Dharminder Chahal (VanHerK Group),
Peter Elmvik (Stockholms Elbolag),
Tord Lendau (Chairman of the Board).

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on May 17, 2023.

Significant events after the period

No significant events have occurred after the end of the period.



Consolidated summary Income Statement

SEK 000'	Oct 1 - Dec 31		Jan 1 - Dec 31	
	2023	2022	2023	2022
Net sales	5 764	4 962	23 245	17 890
Cost of goods sold	-1 527	-1 917	-7 208	-6 655
Gross Profit/Loss	4 236	3 046	16 037	11 235
Sales and marketing expenses	-12 339	-10 132	-42 543	-35 623
Administration expenses	-3 435	-3 195	-12 017	-11 183
Development expenses	-5 165	-3 036	-15 348	-10 816
Other operating income	1	0	1	0
Other operating expenses	103	-317	-69	-32
Operating Income	-16 599	-13 634	-53 939	-46 419
Financial income	-1 388	-1 802	1 193	3 440
Financial expenses	-2 554	-25	-2 838	-194
Profit/Loss before taxes	-20 541	-15 460	-55 585	-43 174
Income tax	0	-	0	0
Profit/Loss for the period	-20 541	-15 460	-55 585	-43 174
Net Profit/Loss attributable to:				
Parent company shareholders	-20 541	-15 460	-55 585	-43 174
Earnings per share based on Net Profit/loss attributable to parent company shareholders (in SEK/share)				
Profit/loss per share (before and after dilution)*	-0,17	-0,23	-0,51	-0,63
Average number of shares outstanding	119 831	68 475	107 980	68 475

Consolidated summary statement of comprehensive income

SEK 000'	Oct 1 - Dec 31		Jan 1 - Dec 31	
	2023	2022	2023	2022
Profit/loss for the period	-20 541	-15 460	-55 585	-43 174
<i>Other comprehensive income for the period:</i>				
<i>Items that have or may be reclassified to profit or loss:</i>				
assets that can be sold				
Translation differences on foreign operations	3 194	1 971	3 127	-2 385
Sum other comprehensive income	3 194	1 971	3 127	-2 385
Total comprehensive income for the period	-17 347	-13 489	-52 458	-45 559
Total comprehensive income attributable to:				
Parent company shareholders	-17 347	-13 489	-52 458	-45 559



Consolidated summary statement of financial position

SEK 000'	Dec 31	
	2023	2022
ASSETS		
<i>Fixed Assets</i>		
Tangible fixed assets	1 709	1 955
Right of use assets	6 893	7 282
Financial fixed assets	0	0
Total Tangible Assets	8 602	9 237
<i>Current Assets</i>		
Inventory	11 919	7 292
Current tax receivable	609	596
Receivables	6 330	9 740
Other current receivables	2 754	4 157
Cash equivalents	34 121	18 832
Total Current Assets	55 732	40 617
Total Assets	64 334	49 854
Shareholders' Equity and Liabilities		
Shareholders' equity attributable to parent company shareholders	43 056	25 237
<i>Longterm Liabilities</i>		
Other longterm liabilities	4 179	5 212
Total Longterm Liabilities	4 179	5 212
<i>Current Liabilities</i>		
Accounts payable	2 871	1 422
Other current liabilities	14 228	17 984
Total Current Liabilities	17 099	19 406
Total Liabilities	21 278	24 617
Total shareholders' equity and liabilities	64 334	49 854



Consolidated change in shareholders' equity

SEK 000'	Share Capital	Other Capital Contributions	Accumulated Loss	Total shareholders' Equity attributable to parent company shareholders
Opening balance Jan 1, 2022	3 424	637 727	-570 354	70 797
Profit/loss for the period			-43 174	-43 174
Other comprehensive income		0	-2 385	-4 771
Total comprehensive income	0	0	-45 559	-47 945
Total transactions with shareholders	0	0	0	0
Closing balance Dec 31, 2022	3 424	637 727	-615 913	22 852
Opening balance Jan 1, 2023	3 424	637 727	-615 913	25 237
Profit/loss for the period			-55 585	-55 585
Other comprehensive income		0	3 127	3 127
Total comprehensive income	0	0	-52 458	-52 458
<i>Transactions with shareholders:</i>				
Ongoing share issue	2 568	77 034		79 602
Issue expenses		-9 326		-9 326
Total transactions with shareholders	2 568	67 708	0	70 276
Closing balance Dec 31, 2023	5 992	705 436	-668 371	43 056

Consolidated summary statement of cash flows

SEK 000'	Oct 1 - Dec 31		Jan 1 - Dec 31	
	2023	2022	2023	2022
Cashflow from operating activities before change in working capital	-16 404	-12 968	-49 851	-42 515
<i>Cashflows from changes in working capital</i>				
Change in Inventory	-1 887	-1 312	-4 627	-492
Change in Receivables	2 284	-5 663	4 800	-6 560
Change in Liabilities	-1 345	5 351	-2 307	5 101
<i>Total change in working capital</i>	-948	-1 625	-2 133	-1 951
Cashflow from operating activities	-17 352	-14 593	-51 984	-44 466
<i>Investment activities</i>				
Acquisitions of Fixed Assets	-83	-208	-383	-381
Cashflow from investment activities	-83	-208	-383	-381
<i>Financing activities</i>				
New share issues	0	0	79 602	0
Expenses related to new share issues	0	0	-9 326	0
Repayment of lease liabilities	-672	-638	-2 595	-2 479
Cashflow from financing activities	-672	-638	67 681	-2 479
Cashflow for the period	-18 107	-15 439	15 314	-47 327
Cash equivalents at start of the year	52 353	34 014	18 832	65 607
Exchange rate differences in cash equivalents	-126	258	-26	552
Cash equivalents at end of the period	34 121	18 832	34 121	18 832



Income statement, Parent Company

SEK 000'	Oct 1 - Dec 31		Jan 1 - Dec 31	
	2023	2022	2023	2022
Net Sales	1 186	1 186	4 744	4 744
Gross profit	1 186	1 186	4 744	4 744
Administration expenses	-3 773	-2 892	-13 393	-11 210
Other Income	1	0	1	0
Other expenses	0	0	-5	-10
Operating Profit/loss	-2 586	-1 706	-8 653	-6 477
<i>Earnings from financial items:</i>				
Profit/Loss from shares in group companies	-12 545	-11 270	-29 438	-23 952
Financial income	246	44	1 021	85
Financial expenses	0	0	0	0
Profit/loss after financial items	-14 885	-12 932	-38 091	-30 344
Taxes	-	-	-	-
Profit/loss for the period	-14 885	-12 932	-38 091	-30 344

Statement of other comprehensive income, Parent Company

SEK 000'	Oct 1 - Dec 31		Jan 1 - Dec 31	
	2023	2022	2023	2022
Profit/loss for the period	-14 885	-12 932	-38 091	-30 344
<i>Other comprehensive income</i>	-	-	-	-
Total other comprehensive income	-	-	-	-
Total comprehensive income	-14 885	-12 932	-38 091	-30 344



Summary Balance Sheet, Parent Company

SEK 000'	Dec 31	
	2023	2022
ASSETS		
<i>Fixed Assets</i>		
Shares in Group Companies	137 647	137 647
Total Fixed Assets	137 647	137 647
<i>Current Assets</i>		
Current receivables and prepaids	50 071	30 397
Cash equivalents	24 132	10 794
Total Current Assets	74 202	41 190
TOTAL ASSETS	211 849	178 837
SHAREHOLDERS' EQUITY AND LIABILITIES		
<i>Shareholder's equity</i>		
Restricted equity		
Share capital	5 992	3 424
Non-restricted equity		
Other capital contributions	705 318	637 610
Retained earnings	-465 724	-435 380
Profit/Loss for the period	-37 071	-30 344
Shareholders equity	208 515	175 309
<i>Current Liabilities</i>		
Current liabilities	3 334	3 527
Total liabilities	3 334	3 527
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	211 849	178 837



Notes

Note 1 Accounting principles

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. For the Parent Company, the interim report has been prepared in accordance with the Annual Accounts Act and the Swedish Securities Market Act in accordance with the provisions of RFR 2. For both the Group and the Parent Company the same accounting principles and bases for calculation have been applied as in its most recent Annual Report with the exception of what is stated below. Significant accounting and valuation principles are detailed on pages 47–52 of the consolidated annual report for 2022.

Note 2 Fair value of financial instruments

Current receivables and liabilities

For current receivables and liabilities, such as accounts receivable and accounts payable with a maturity of less than six months, the carrying amount is considered to reflect fair value.

Note 3 Contingent Liabilities

The Parent Company issued a capital adequacy guarantee to its wholly owned subsidiary SciBase AB to secure that the equity at minimum corresponds to the share capital that is valid until the end of 2023. A corresponding agreement was in-place in 2022, 2021, 2020, 2019, 2018, 2017, 2016, 2015 and 2014 as well.

Note 4 Seasonal effects

To a certain extent, SciBase's sales and operating profit are expected to be dependent on seasonal variation that the company cannot influence. In the third quarter, due to the vacation period, the number of tests performed is expected to decrease and consequently the company's sales are also expected to dip.

Note 5 Information regarding operating segments

The Group has today two operating segments, skin cancer and skin barrier assessment. Follow-ups are in addition done on the geographical areas, Europe, US/North America and Asia/Oceania.

Fourth quarter

Skin cancer

Europe

Net sales during the period amounted to TSEK 4,758 (3,674) of which Germany accounted for 100 (100)%. In the period the focus for the sales and marketing effort has continued to be Germany with the Company's own sales organization. Gross profit amounted to a profit of TSEK 3,586 (2,106).

Other geographical areas

Net sales during the period amounted to TSEK 527 (399). The sales consisted mainly of electrode sales to larger dermatology groups. Gross profit amounted to TSEK 337 (340).

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas

since they presently do not amount to a substantial portion of the total.

Skin barrier assessment

Europe

Net sales during the period amounted to TSEK 265 (32). Gross profit amounted to a profit of TSEK 147 (15). The sales were to researchers within the skin barrier field.

Other geographical areas

Net sales during the period amounted to TSEK 215 (857). Gross profit amounted to TSEK 167 (584). The sales were to researchers and pilot sales to a distributor in Japan.

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

January - December

Skin cancer

Europe

Net sales during the period amounted to TSEK 20,189 (13,699) of which Germany accounted for 100 (100)%. In the period the focus for the sales and marketing effort has continued to be Germany with the Company's own sales organization. Gross profit amounted to a profit of TSEK 14,057 (8,207).

Other geographical areas

Net sales during the period amounted to TSEK 1,638 (2,608). Gross profit amounted to TSEK 1,212 (1,987). The sales consisted mainly of electrode sales to larger dermatology groups. 2022 included the sales of 10 Nevisense to the Company's partners in the US.

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

Skin barrier assessment

Europe

Net sales during the period amounted to TSEK 550 (389). Gross profit amounted to a profit of TSEK 317 (215). The sales were to researchers within the skin barrier field.

Other geographical areas

Net sales during the period amounted to TSEK 869 (1,194). Gross profit amounted to TSEK 451 (826). The sales were to researchers, industry as well as pilot sales to a distributor in Japan within the skin barrier field.

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

Note 6 Incentive program

The Group has no outstanding warrants. The Board considers it as important and positive if the employees' ownership in the company increases. The Board has evaluated different incentive programs and following this decided to implement a normal bonus program. The goals are set by the board and normally consist of turnover

goals and other strategic goals. After the end of the year, it is then assessed how well the goals have been met. However, the purpose of the program is to increase the employees' ownership in the company. The board sees increased ownership by the employees as positive as it increases the employees' incentive for the company to succeed through, for example, increased sales and thereby creating increased shareholder value. Thus, if the employee undertakes to buy shares over the market and enter into a lockup agreement (12-months), the bonus is

increased by 4 times the cash bonus. The program has a maximum ceiling (including social security fees etc of SEK 3 million). For the full year 2022 the total cost was SEK 0.9 million. For 2023, an accrual of MSEK 1.2 for the corresponding program has been made. The outcome of the program is dependent upon reaching the set targets.

Operating segments

SEK 000'	Oct 1 - Dec 31, 2023			Oct 1 - Dec 31, 2022		
	Europe	Rest of the World	Total	Europe	Rest of the World	Total
Skincancer - Net sales	4 758	527	5 284	3 674	399	4 073
The skin barrier function - Net Sales	265	215	480	32	857	889
Sales between segments	-	-	-	-	-	-
Net sales from external customers	5 022	742	5 764	3 706	1 256	4 962
Cost of goods - Skincancer	-1 172	-190	-1 362	-1 568	-59	-1 627
Cost of goods - Barrier function	-118	-48	-166	-17	-273	-290
Cost of goods - total	-1 290	-238	-1 527	-1 585	-332	-1 917
Gross Profit - Skincancer	3 585	337	3 923	2 106	340	2 446
Gross Profit - Barrier function	147	167	314	15	584	599
Gross Profit - total	3 732	504	4 236	2 122	924	3 046
Operating expenses			-20 835			-16 680
Operating profit/Loss			-16 598			-13 634
Financial Income			-1 388			-1 802
Financial Expenses			-2 554			-25
Group earnings - before tax			-20 541			-15 460

SEK 000'	Jan 1 - Dec 31, 2023			Jan 1 - Dec 31, 2022		
	Europe	Rest of the World	Total	Europe	Rest of the World	Total
Skincancer - Net sales	20 189	1 638	21 826	13 699	2 608	16 307
The skin barrier function - Net Sales	550	869	1 419	389	1 194	1 583
Net sales from external customers	20 739	2 506	23 245	14 088	3 802	17 890
Cost of goods - Skincancer	-6 131	-426	-6 558	-5 493	-621	-6 113
Cost of goods - Barrier function	-233	-418	-651	-174	-368	-542
Cost of goods - total	-6 364	-844	-7 208	-5 666	-989	-6 655
Gross Profit - Skincancer	14 057	1 211	15 268	8 207	1 987	10 194
Gross Profit - Barrier function	317	451	768	215	826	1 041
Gross Profit - total	14 374	1 662	16 037	8 422	2 813	11 235
Operating expenses			-69 976			-57 654
Operating profit/Loss			-53 939			-46 418
Financial Income			1 193			3 440
Financial Expenses			-2 838			-194
Group earnings - before tax			-55 585			-43 173



Net sales per category and segment

Amounts in KSEK	Oct 1 -Dec 31 2023		Oct 1 - Dec 31 2022		Jan 1 - Dec 31 2023		Jan 1 - Dec 31 2022	
	Europe	Rest of the World	Europe	Rest of the World	Europe	Rest of the World	Europe	Rest of the World
<i>Skin cancer</i>								
Electrodes	4 371	502	3 340	387	18 942	1 452	12 402	2 038
Instruments	387	25	335	11	1 247	185	1 297	570
Total Skin Cancer	4 758	527	3 675	398	20 189	1 638	13 699	2 608
<i>Skin barrier function</i>								
Electrodes	130	113	32	509	257	252	275	604
Instruments	134	102	0	348	293	617	114	590
Total skin barrier function	265	215	32	857	550	869	389	1 194
<i>Total</i>								
Electrodes	4 501	615	3 372	896	19 199	1 704	12 677	2 642
Instruments	521	127	335	359	1 540	802	1 411	1 160
Total	5 023	742	3 707	1 256	20 739	2 506	14 088	3 802

Signatures

The Board of Directors and the President provide their assurance that this interim report provides an accurate view of the operations, position and earnings of the Group and the Parent Company, and that it also describes the principal risks and uncertainties faced by the Parent Company and the companies included within the Group.

[SciBase Holding AB]
Stockholm, February 21, 2024

Tord Lendau
Chairman of the Board

Diana Ferro
Board member

Thomas Taapken
Board member

Matt Leavitt
Board member

Jvalini Dwarkasing
Board member

Pia Renaudin
CEO

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on February 21, 2024.

This year-end report has not been subject to review by the Company's auditors

This report, together with previously published interim reports, can be found in its entirety on the company's website: <http://investors.scibase.se/en/reports-and-presentations>

Contact person:
Michael Colérus, CFO, +46 70 341 34 72

Quarterly overview

THE GROUP	Q4	Q3	Q2	Q1	Q4	Q3	Q2	Q1	Q4
Net sales, SEK ths	5 764	7 248	5 085	5 149	4 962	4 941	3 726	4 260	3 925
Gross margin, %	73,5%	68,2%	65,3%	68,7%	61,4%	58,4%	70,6%	62,8%	52,8%
Equity/Asset ratio, %	66,9%	72,4%	73,7%	77,9%	50,6%	72,5%	76,6%	79,3%	82,8%
Net indebtedness, multiple	0,49	0,38	0,36	0,28	0,98	0,38	0,30	0,26	0,21
Cash equivalents, SEK ths	34 121	52 353	70 874	14 394	18 832	34 014	44 577	54 621	65 607
Cashflow from operating activities, SEK ths	-17 352	-17 827	-13 054	-3 751	-14 593	-9 718	-9 643	-10 512	-11 709
Earnings per share (before and after dilution), SEK	-0,17	-0,11	-0,16	-0,15	-0,23	-0,13	-0,13	-0,14	-0,20
Shareholder's equity per share, SEK	0,36	0,50	0,60	1,19	0,37	0,57	0,72	0,88	1,03
Average number of shares, 000'	119 831	119 831	119 831	72 426	68 475	68 475	68 475	68 475	68 475
Number of shares at closing of period, 000'	119 831	119 831	119 831	119 831	68 475	68 475	68 475	68 475	68 475
Share price at end of period, SEK	0,83	1,24	1,19	1,80	3,82	3,70	3,41	4,70	5,52
Number of sold electrodes, pieces	12 044	16 922	11 330	11 614	11 444	10 592	9 550	9 982	8 024
Average number of employees	26	23	22	21	21	20	19	18	18

Definitions

Financial key ratios

- **TSEK:** SEK 000'
- **Gross margin, %:** Gross profit divided by net sales.
- **Operating profit:** Operating income less operating expenses.
- **Operating margin, %:** Operating profit divided by income.
- **Equity/assets ratio:** Equity at the end of the period divided by total assets at the end of the period.
- **Debt/equity ratio:** Total liabilities in relation to equity.
- **Earnings per share for the period before dilution:** Profit for the period divided by average number of shares before dilution.
- **Earnings per share for the period after dilution:** Profit for the period divided by average number of shares after dilution. Earnings per share after dilution is the same as before dilution because potential ordinary shares do not cause to dilution.
- **Shareholders' equity per share:** Equity divided by average number of shares.
- **Dividend per Share:** Dividend for the period divided by average number of shares after dilution.
- **Number of shares before dilution at the end of the period:** Number of shares in issue before dilution at the end of the period.
- **Average number of shares before dilution:** Average number of shares during the period before dilution.
- **Average number of shares after dilution:** Average number of shares in issue after dilution is the same as before dilution because potential ordinary shares do not cause to dilution.
- **Number of employees (average):** Weighted average number of employees in the relevant period.
- **IFRS:** International Financial Reporting Standards

Industry specific glossary

- **CE labeling:** A mandatory conformity marking to show that products sold within the European Economic Area (EEA) since 2008 fulfills the requirements of the acquis. CE labeling is also included on products sold outside the EEA but that are produced in the EEA, or intended for sale there.
- **Dermatoscopy or Dermoscopy:** Examination of skin lesions with a dermatoscope, a strong magnifying glass with a built-in light source.
- **Electrical Impedance Spectroscopy (EIS):** A measure of the overall impedance occurring in tissue when alternating current is applied at a series of alternating frequencies. This is measured by transmitting an imperceptible alternating current between the bands on the electrode, which is mounted on the tip of the probe and measures the current.
- **FDA:** The US Food and Drug Administration is the US authority controlling all aspects of the development, manufacture and commercialization of pharmaceutical products and medical devices in the United States.
- **Melanoma:** The most dangerous form of skin cancer, consisting of cancer in pigment-producing melanocytes.
- **Unnecessary excision:** The removal of benign skin lesions/birthmarks.
- **Nevi:** Lesions.
- **PMA:** Pre-Market Approval, a form of approval from the US FDA required for all new Class III devices.

Alternative performance measures (APM)

This section contains a reconciliation of certain alternate performance measures (APM) against the most reconcilable items in the financial statements. The reporting of APMs has limitations as analytical tools and should not be viewed without context or as compensation for financial measures prepared in accordance with IFRS. APMs are reported to improve investors' evaluation of ongoing operating profit, as a means of predicting future periods, and to simplify a meaningful comparison of results between periods. Management uses these APMs to evaluate, among other things, ongoing operations compared with previous results, for internal planning and forecasting, as well as for calculation of certain performance-related compensation. The APMs reported in this interim report may differ from measures with similar terms used by other companies.

APM for the period:

Gross Margin (%)

	2023	2022
Gross Profit	16 037	11 235
Net Sales	23 245	17 890
Gross Margin (%)	69,0%	62,8%

Definition:

Gross Profit / Loss divided with Net Sales.

Cause of use:

The gross margin shows the difference between net sales and the cost of goods sold in % of net sales. The gross margin is affected by several factors such as product mix, price trends, exchange rate fluctuation, efficiency in manufacturing processes etc. This is an important measurement as it provides a better understanding of the Company's progress.

Shareholder Equity ratio (%)

	2023	2022
Total Shareholders' Equity	43 056	25 237
Total Assets	64 334	49 854
Shareholders' Equity ratio (%)	66,9%	50,6%

Definition:

Total Shareholders' Equity at the end of the period divided with Total Assets at the end of the year.

Cause of use:

Shareholders equity ratio shows the Group's financial sustainability and the portion that is financed by equity.

Debt ratio (times)

	2023	2022
Total Liabilities	21 278	24 617
Total Shareholders' Equity	43 056	25 237
Debt ratio (times)	0,49	0,98

Definition:

Total debt in relation to Total Shareholders' Equity.

Cause of use:

The debt ratio indicates how much debt the Company is using to finance its assets relative to the value of shareholders' equity. It is closely connected to the Shareholder's equity ratio.

Earnings per share, after dilution (sek)

	2023	2022
Profit/Loss for the period	-55 585	-43 174
Average number of shares (thousand)	107 980	68 475
Earnings per share (sek)	-0,51	-0,63

Definition:

Is the portion of a company's profit allocated to each outstanding share of common stock after dilution. The result per share after the dilution is no different than before the dilution due to that potential common stock do not give rise to a dilution effect.

Cause of use:

This shows the value per share.

Shareholders' equity per share (sek)

	2023	2022
Shareholders' Equity	43 056	25 237
Average number of shares (thousand)	107 980	68 475
Shareholders' equity per share	0,40	0,37

Definition:

Shareholders' equity divided with the average number of shares after dilution

Cause of use:

The shareholders' equity per share provides a measure of the net worth per share and can be set in relation to the actual stock price

Average number of shares (thousand)

	2023	2022
Opening balance - Jan 1	68 475	68 475
Closing balance - Sep 30	119 831	68 475
Average number of shares (thousand)	107 980	68 475

Definition:

The average number of issued shares.

Cause of use:

The average number of shares gives a more accurate picture of the result and shareholders' equity due to the fact that the number of shares can change.



Pia Renaudin
CEO
+46 73 206 98 02
simon.grant@scibase.com

Read more about the company and its operations
at our website >> www.scibase.com



Michael Colérus
CFO
+46 70 341 34 72
michael.colerus@scibase.com

Future reporting dates

Interim report Q1 2024, May 9 2024

Annual report, week 16

AGM 2024, May 17 2024

Interim report Q2 2024, August 21 2024

Interim report Q3 2024, November 12 2024